We also identify key regulatory axes, such as CD47/Sirpa and Selplg/Vsir in AAA, and CD48/CD2, CD86/CD80, and CTLA-4/PD-1 in atherosclerosis, as potential therapeutic targets. This evidence concerns the gene CD86 and triple-A syndrome.